EUVIMEDEUVIMED entdecken
CrossrefInfokarte

RECIPIENT-TO-DONOR ANTI-CMV IGG RATIO AS A PREDICTOR OF CMV REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE-CONTROL STUDY

Siwar Frigui, Salma Daly, Samia Rekaia, Yosra Chebbi, Hedia Bellali, Monia Ben Khaled, Monia Ouederni, Wafa Achour

Mediterranean Journal of Hematology and Infectious Diseases · 2026-10-31 · 18 (1) · e2026078

DOI: 10.4084/mjhid.2026.078 ↗
AbstractBibliografische Angaben

Abstract

Background: Despite advances in diagnosis and treatment, cytomegalovirus (CMV) reactivation remains a serious complication following allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). Our objectives were to explore the impact of pre-transplant anti-CMV IgG titers in both donor and recipient on the occurrence of post-transplant CMV reactivation and to determine a threshold titer that would allow for better stratification of the post-transplant reactivation risk. Methods: We conducted a unicentric retrospective case-control study involving pediatric allo-HSCT recipients. All donors were related (genotypically identical or haploidentical). CMV reactivation was defined by a viral load ≥ 150 IU/ml in plasma. We included 24 cases (patients who had an episode of CMV reactivation in the first 100 days after HSCT) and 48 randomly selected controls (patients without CMV reactivation in the first 100 days after HSCT). Results: In univariate analysis, factors associated with CMV reactivation were D-/R+ pre-transplant CMV serostatus (p=0.013), recipient anti-CMV IgG titer (p=0.012), R/D anti-CMV IgG ratio (p=0.049), HLA haploidentical related donor (p=0.0001), GvHD prophylaxis with combination of cyclosporin A, cyclophosphamide and mycophenolate mofetil (p=0.0001), acute GvHD (p=0.001) and corticosteroids (p=0.0001). Donor anti-CMV IgG titer was a protective factor (p=0.046). Multivariate analysis showed that male donor gender (adjusted OR=4.919; 95% CI (1.103 – 21.942); p=0.037), D-/R+ pre-transplant CMV serologic status (adjusted OR=6.874; 95% CI (1.372 – 34.444); p=0.019), recipient anti-CMV IgG titer (adjusted OR=1.005; 95% CI (1.000 – 1.010); p=0.033), HLA haploidentical related donor (adjusted OR=5.472; 95% CI (1.334 – 22.453); p=0.018) and acute GvHD (OR=7.116; 95% CI (1.770 – 28.604) ; p=0.006) were independent risk factors for CMV reactivation after allo-HSCT. ROC curve analysis showed that the optimal cut-off value to predict CMV reactivation was 113.75 AU/ml for the recipient anti-CMV IgG titer (Se=72.2%; Sp= 64.9%; AUC=0.701; p=0.016) and 1 for the R/D anti-CMV IgG ratio (Se=77.8%; Sp=78.4%; AUC=0.814; p113.75 AU/mL (50% versus 16%; p= 0.002) and in those with R/D anti-CMV IgG ratio >1 (64% versus 15%; p

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →